Komori
OncoTherapy Science (4564) · InitiativeDecrease in outstanding unexercised options

Providing incentives to officers, employees and outside collaborators through stock options

First written in FY2020. 2 of 8 entries say "Dropped", first in FY2025-H1. Latest entry: FY2026.

8entries
7years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2020 – FY20262020: 120202021: 120212022: 020222023: 120232024: 220242025: 120252026: 22026
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 658 companies write about · 0 as a headwind · 739 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 741 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Decrease in outstanding unexercised optionsAnnual report

    「Outstanding unexercised balance 1,280,000」

    The outstanding unexercised balance of stock options decreased by 10,000 shares from the previously reported 1,290,000 shares to 1,280,000 shares.
  2. 2026-05-08DroppedOccurring Fact

    「As some of the Stock Acquisition Rights previously issued as stock options ceased to meet the exercise requirements stipulated in their terms, they were extinguished pursuant to Article 287 of the Companies Act, and the Company recognized reversal of Stock Acquisition Rights of ¥0 million.」

    Some of the previously issued stock options were extinguished because they no longer met the exercise requirements. This concerned the cancellation and extinguishment of some Stock Acquisition Rights, not the scheme as a whole.
  3. FY2025Continued disclosure of outstanding unexercised balanceAnnual report

    「Outstanding unexercised balance 1,290,000」

    Under the stock option program, 40,000 shares expired from the previously reported outstanding unexercised balance of 1,330,000 shares, and an outstanding unexercised balance of 1,290,000 shares was disclosed.
  4. FY2025-H1DroppedAnnual report

    「① [Details of the stock option plan] No applicable matters.」

    It was stated that there were no applicable matters concerning the stock option program during the current interim consolidated accounting period.
  5. FY2024Decrease in outstanding unexercised optionsAnnual report

    「Outstanding unexercised balance 1,330,000」

    The outstanding unexercised balance of stock options became 1,330,000 shares, down from the previously reported unvested balance of 1,435,000 shares.
  6. FY2023Decrease in unvested balanceAnnual report

    「Unvested balance - 1,435,000」

    For the stock options approved on 24 June 2020, the unvested balance before vesting became 1,435,000 shares, after deducting 370,000 forfeited shares from 1,805,000 shares.
  7. FY2022-Q1RestatedAnnual report

    「Class, description and number of shares underlying the stock acquisition rights* ① Common shares 1,785,000 ② Common shares 100,000 Exercise period for the stock acquisition rights* ① 16 June 2023 ~10 June 2031 ② 16 June 2023 ~10 June 2031」

    The Company continues to disclose the terms of stock options granted to officers, employees and external collaborators.
  8. FY2020First statedAnnual report

    「To increase the motivation and morale of the Company's and its affiliates' directors, employees, audit & supervisory board members, prospective employees and external collaborators to improve the Group's performance, the Company will issue stock acquisition rights to them free of charge, without requiring any monetary payment.」

    The Company disclosed a policy of granting stock acquisition rights free of charge as a means of increasing the motivation and morale of officers, employees, prospective employees, audit & supervisory board members and external collaborators to improve performance.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet. It last moved in the Occurring Fact of 2026-05-08: "Dropped".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Providing incentives to officers, employees and outside collaborators through stock options | OncoTherapy Science,Inc. (4564) | Komori